Ikena Oncology, Inc. (NASDAQ:IKNA – Get Rating) – Investment analysts at William Blair decreased their Q4 2022 earnings per share estimates for shares of Ikena Oncology in a report released on Tuesday, November 8th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Ikena Oncology’s current full-year earnings is ($1.95) per share. William Blair also issued estimates for Ikena Oncology’s Q1 2023 earnings at ($0.54) EPS, Q2 2023 earnings at ($0.56) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.65) EPS and FY2023 earnings at ($2.33) EPS.
Ikena Oncology (NASDAQ:IKNA – Get Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09).
Ikena Oncology Stock Down 3.6 %
Ikena Oncology stock opened at $2.12 on Thursday. The business has a 50 day moving average price of $3.50 and a two-hundred day moving average price of $4.14. The stock has a market cap of $76.86 million, a price-to-earnings ratio of -1.46 and a beta of 0.63. Ikena Oncology has a 12 month low of $2.00 and a 12 month high of $17.50.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. State Street Corp raised its stake in shares of Ikena Oncology by 18.8% in the 1st quarter. State Street Corp now owns 404,602 shares of the company’s stock valued at $2,468,000 after purchasing an additional 63,988 shares during the period. Millennium Management LLC bought a new position in Ikena Oncology during the second quarter worth about $1,045,000. Charles Schwab Investment Management Inc. grew its holdings in Ikena Oncology by 5.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock worth $408,000 after purchasing an additional 3,276 shares during the period. Goldman Sachs Group Inc. grew its holdings in Ikena Oncology by 103.0% during the first quarter. Goldman Sachs Group Inc. now owns 26,119 shares of the company’s stock worth $160,000 after purchasing an additional 13,255 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Ikena Oncology by 25.4% during the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock worth $104,000 after purchasing an additional 3,482 shares during the period. Institutional investors and hedge funds own 73.90% of the company’s stock.
Ikena Oncology Company Profile
Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- Get a free copy of the StockNews.com research report on Ikena Oncology (IKNA)
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Coupang Stock And Why You Should Care
- This Is No Time To Buy D.R. Horton Stock
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.